Elypta AB’s urine-based test correctly identified 90% of patients whose kidney cancer had returned, according to results from an ongoing study. The company’s metabolism-based liquid biopsy platform, ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...